Hanchung Medical announced that it has signed a nationwide distribution agreement in Japan for ASCE+ SRLV E, a Japan-exclusive skin booster line developed by Korean biotech company ExoCoBio and based on exosome technology.

Under the agreement, Hanchung Medical will introduce the Japan-specific lineup of ASCE+ SRLV E and gradually expand product supply to medical institutions across Japan. In collaboration with its local distribution partner, the company will operate product information and consultation channels to support early market establishment.

According to the company, ASCE+ SRLV E is a freeze-dried regenerative and anti-aging skin booster formulated with stem cell–derived exosomes. Based on official product information, it is positioned as a treatment option for improving overall skin quality, including wrinkle appearance, skin tone and texture (pores), and acne scars.

Hanchung Medical stated,

“We will support stable supply and safe usage by providing labeling and usage guidelines in compliance with Japanese regulations.”

The company added,

“This nationwide supply agreement in Japan represents a key milestone in our Northeast Asia expansion strategy.”